Odyssey Therapeutics, Inc.
Odyssey Therapeutics, Inc. is a U.S.-based clinical-stage biopharmaceutical company focused on discovering and developing medicines for autoimmune and inflammatory diseases. Its pipeline centers on small-molecule and other precision therapies designed to target disease pathways such as RIPK2 and SLC15A4, with development activities organized around preclinical and clinical programs.
Liiketoiminta
Osuus liikevaihdostaDrug candidates in human trials, including OD-001 and other pipeline assets.
Research-stage programs aimed at identifying and validating new immune targets.
Revenue from research collaborations, material transfer, option, and license agreements.
Asiakkaat
Odyssey does not sell approved products today; its near-term counterparties are pharmaceutical collaborators and research partners that support discovery and development programs. If its candidates are approved, the end customers would be physicians, hospitals, patients, and third-party payors in autoimmune and inflammatory disease markets.
Companies that enter research, option, or license agreements to access Odyssey's programs and data.
Patients with ulcerative colitis, inflammatory bowel disease, lupus, and related disorders who would use approved therapies.
Prescribers who would adopt the therapies if clinical data, safety, and convenience support use.
Insurers and reimbursement bodies that determine access and utilization for approved medicines.
Strategia
Odyssey's strategy is to advance precision medicines for autoimmune and inflammatory diseases, with emphasis on translating target biology into differentiated clinical candidates. It is also building a broader pipeline through discovery, collaboration, and intellectual property development so that multiple programs can progress in parallel.
Clinical proof-of-concept is the key step toward later-stage value creation and eventual approval.
Multiple programs reduce single-asset dependence and create more shots on goal in immune disease.
Discovery-stage biopharma requires external capital and partnering to fund long development timelines.
Maantiede
Odyssey is headquartered in the United States and conducts its research and development activities from that base. Its business is primarily U.S.-centric today, while collaboration, regulatory, and eventual commercialization exposure could extend to other markets if programs advance.
Riskit
Odyssey faces the core risks of clinical-stage biotechnology: uncertain trial outcomes, regulatory approval risk, and the possibility that product candidates never reach commercialization. Its business also depends on capital access, third-party manufacturing, and successful collaboration execution, while autoimmune drug development carries safety, efficacy, reimbursement, and market-adoption risk.
- Funding and liquidity dependenceVaikutus: KorkeaTodennäköisyys: Korkea
Research and clinical programs require substantial capital before any product revenue exists.
Kohdistuu: Corporate operations and pipeline advancement
- Clinical development failureVaikutus: KorkeaTodennäköisyys: Kohtalainen
The company depends on positive efficacy and safety data to move candidates forward.
Kohdistuu - Regulatory approval riskVaikutus: KorkeaTodennäköisyys: Kohtalainen
Even successful trials may not translate into marketing authorization.
Kohdistuu: All product candidates
- Third-party manufacturing relianceVaikutus: KeskitasoTodennäköisyys: Kohtalainen
Clinical supply depends on CMOs meeting quality, timing, and scale requirements.
Kohdistuu: Drug substance and drug product supply
- Market acceptance and reimbursementVaikutus: KeskitasoTodennäköisyys: Kohtalainen
Approved therapies must win physician, patient, and payor adoption to generate revenue.
Kohdistuu: Future commercial products
- Product liability and safety eventsVaikutus: KeskitasoTodennäköisyys: Kohtalainen
Unexpected adverse events can create legal exposure and damage adoption.
Kohdistuu: Clinical and future commercial products
Kirjanpito
Harkinnanvaraiset erätRevenue from Pfizer MTA and J&J collaboration arrangements depends on contract accounting and timing of deliverables.
Vaikutus: Can create uneven quarterly revenue
Clinical and preclinical vendor services are often recognized before cash payment.
Vaikutus: Affects operating expense timing
Equity awards are a major non-cash expense for a public biotech company.
Vaikutus: Impacts reported losses and dilution analysis
The Rahko acquisition includes milestone-based contingent payments measured at fair value.
Vaikutus: Can introduce non-operating volatility
Samankaltaisia listattuja yhtiöitä
Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.
Ovid Therapeutics Inc.
OVID · Pharmaceutical Preparations
Odyssey Health, Inc.
ODYY · Surgical & Medical Instruments & Apparatus
Apogee Therapeutics, Inc.
Biological Products, (No Diagnostic Substances)
Ventyx Biosciences, Inc.
Pharmaceutical Preparations
Aldeyra Therapeutics, Inc.
ALDX · Pharmaceutical Preparations
Aldeyra Therapeutics is a clinical-stage biotechnology company focused on discovering and developing therapies for immune-mediated diseases.
OS Therapies Inc
OSTX · Pharmaceutical Preparations
OS Therapies Inc is a U.S.-based clinical-stage biopharmaceutical company focused on developing immunotherapy and targeted cancer candidates.
Päivitetty: 24.9.2026